Research programme: recombinant immunoglobulin P technology - MultiCell Technologies
Latest Information Update: 08 Jun 2010
At a glance
- Originator MultiCell Technologies Inc
- Class
- Mechanism of Action Immunologic receptor agonists; Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Diabetes mellitus; Multiple sclerosis
Most Recent Events
- 29 Mar 2007 Preclinical trials in Cancer in USA (unspecified route)
- 29 Mar 2007 Preclinical trials in Diabetes mellitus in USA (unspecified route)
- 29 Mar 2007 Preclinical trials in Multiple sclerosis in USA (unspecified route)